Roivant Sciences announced that Srini Ramanathan, Ph.D. will be joining the company as Chief Development Officer. Dr. Ramanathan has over 20 years of drug development expertise across a wide range of diseases. He joins Roivant from Horizon Therapeutics where he served as Senior Vice President of Research and Development Sciences and Site Head of the South San Francisco office.

At Horizon, Dr. Ramanathan was responsible for building various scientific functions in discovery and development supporting pipeline expansion, regulatory submissions, and business development activities. Earlier in his career, he served in leadership roles at AbbVie and Gilead Sciences. He has contributed to the global approval of several medicines in virology, oncology, and autoimmune disease, and has published extensively in peer-reviewed journals.